Ethiqa XR® is a pharmaceutical-grade, extended-release formulation of buprenorphine, indexed by the U.S. Food and Drug Administration (FDA) for the management of post-operative pain in laboratory rodents.

This long-acting opioid has been approved by the Danish Medicines Agency for use in mice and rats, providing sustained analgesia for up to 72 hours following a single administration.

A single subcutaneous dose reduces both animal handling and procedural stress, thereby enhancing animal welfare and minimizing experimental variability. This approach aligns with best practices and recommendations from the Animal Experiments Inspectorate.

Investigators are encouraged to consult with facility veterinarians for guidance on the appropriate integration of Ethiqa XR® into their study protocols.